KR920006317A - 칼슘 흡수 억제제 - Google Patents

칼슘 흡수 억제제 Download PDF

Info

Publication number
KR920006317A
KR920006317A KR1019910016528A KR910016528A KR920006317A KR 920006317 A KR920006317 A KR 920006317A KR 1019910016528 A KR1019910016528 A KR 1019910016528A KR 910016528 A KR910016528 A KR 910016528A KR 920006317 A KR920006317 A KR 920006317A
Authority
KR
South Korea
Prior art keywords
patient
compound
acceptable salt
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
KR1019910016528A
Other languages
English (en)
Other versions
KR100198045B1 (ko
Inventor
죠셉 디너스타인 로버트
스티븐 새이볼 제프리
앨런 디케마 케이스
Original Assignee
게리 디. 스트리트
메렐 다우 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디. 스트리트, 메렐 다우 파마슈티칼즈 인코포레이티드 filed Critical 게리 디. 스트리트
Publication of KR920006317A publication Critical patent/KR920006317A/ko
Application granted granted Critical
Publication of KR100198045B1 publication Critical patent/KR100198045B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/08—Preparation by ring-closure
    • C07D213/09—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles
    • C07D213/10—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from acetaldehyde or cyclic polymers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

내용 없음

Description

칼슘 흡수 억제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 래트(rat)복강의 호중구 칼슘의 fMLP활성화에 대한 3종의 디아릴 아세틸렌 케톤의 효과를 도시한다.

Claims (33)

  1. 하기 일반식(Ⅰ)화합물:
    상기식에서, R1, R2및 R3은 각각 독립적으로 수소, C1-C6알킬, C1-C6알콕시, 할로겐, -N(Y1)(Y2)이고, 여기서, Y1및 Y2는 각각 독립적으로 수소 또는 C1-C6알킬이거나 Xz-(Q)-(CH2)n-O-이고, 이때 Q는 페닐 또는 나프틸이고, n은 0 또는 1이며 x는 C1-C6알콕시 또는 -N(Y1)(Y2)(여기서, Y1및 Y2는 상기에서 정의한 바와 같다)이고 z는 0,1 또는 2이고, Ar은 하기 일반식
    (여기서, R1, R2및 R3는 상기에서 정의한 바와 같다)의 라디칼이다.
  2. 제1항에 있어서, 1-(4-디메틸아미노페닐)-3-(4-피리딘일)-2-프로펜-1-온인 화합물.
  3. 제1항에 있어서, 1-페닐-3-(4-피리딘일)-2-프로펜-1-온인 화합물.
  4. 제1항에 있어서, 1-페닐-3-(3-피리딘일)-2-프로펜-1-온인 화합물.
  5. 제1항에 있어서, 1-(4-디메틸아미노페닐)-3-(4-피리딘일)-2-프로펜-1-온인 화합물.
  6. 제1항에 있어서, 1-페닐-3-(2-이미다졸릴)-2-프로펜-1-온인 화합물.
  7. 제1항에 있어서, 1-페닐-3-(티오펜-2-일)-2-프로펜-1-온인 화합물.
  8. 제1항에 있어서, 1-페닐-3-(2-푸란일)-2-프로펜-1-온인 화합물.
  9. 제1항에 있어서, 1-(4-디에틸아미노페닐)-3-(4-피리딘일)-2-프로펜-1-온인 화합물.
  10. 제1항에 있어서, 1-(4-디에틸아미노페닐)-3-(4-퀴놀린일)-2-프로펜-1-온인 화합물.
  11. 백혈구에서의 칼슘흡수를 억제시킬 필요가 있는 환자에게 제1항에 따른 일반식(1)화합물을 칼슘 흡수 억제 유효량으로 투여함을 특징으로 하여 상기한 환자의 백혈구에서의 칼슘흡수를 억제시키는 방법.
  12. 제11항에 있어서, 환자가 면역성 질환 환자인 방법.
  13. 제11항 또는 제12항에 있어서, 환자가 변형관절염 환자인 방법.
  14. 제11항 또는 제12항에 있어서, 환자가 면역성 맥관염환자인 방법.
  15. 제11항에 있어서, 환자가 염증성 질환 환자인 방법.
  16. 제11항에 있어서, 환자가 호중구 피부병 환자인 방법.
  17. 혈소판에서의 칼슘흡수를 억제시킬 필요가 있는 환자에게 제1항에 따른 일반식(1)화합물을 칼슘 흡수 억제 유효량으로 투여함을 특징으로 하여 상기한 환자의 혈소판에서의 칼슘흡수를 억제시키는 방법.
  18. 제17항에 있어서, 환자가 심장혈관질환 환자인 방법.
  19. 제17항에 있어서, 환자가 심장수축경색증 환자인 방법.
  20. 제17항에 있어서, 환자가 허혈재관류 환자인 방법.
  21. 제1항 내지 제10항중 어느 한 항에 따른 화합물을 담체와 혼합되어 포함하는 약제학적 조성물.
  22. 약제학적 활성물질로서 사용하기 위한, 제1항 내지 제10항중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용되는 염 또는 이의 혼합물.
  23. 치료용 약제학적 조성물을 제조하는데 백혈구에서의 칼슘 흡수 억제제로서 사용하기 위한 제1항 내지 제10항중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용되는 염 또는 이의 혼합물.
  24. 면역성질환 치료용 약제학적 조성물을 제조하는데 사용하기 위한 제23항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  25. 변형관절염 치료용 약제학적 조성물을 제조하는데 사용하기 위한 제23항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  26. 면역성맥관염 치료용 약제학적 조성물을 제조하는데 사용하기 위한 제23항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  27. 염증성질환 치료용 약제학적 조성물을 제조하는데 사용하기 위한 제23항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  28. 호중구 피부병 치료용 약제학적 조성물을 제조하는데 사용하기 위한 제23항에 따른 화합물 또는 이의 약제학적으로 허용되는 염.
  29. 치료용 약제학적 조성물을 제조하는데 혈소판에서의 칼슘 흡수 억제제로서 사용하기 위한, 제1항 내지 제10항중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용되는 염 또는 이의 혼합물.
  30. 심장혈관질환 치료용 약제학적 조성물을 제조하는데 사용하기 위한 제29항에 따른 이의 약제학적으로 허용되는 염.
  31. 허혈재관류 치료용 약제학적 조성물을 제조하는데 사용하기 위한 제29항에 따른 이의 약제학적으로 허용되는 염.
  32. 심장수축경색증 치료용 약제학적 조성물을 제조하는데 사용하기 위한 제29항에 따른 이의 약제학적으로 허용되는 염.
  33. 본원에 기술한 바와 같은 합성도식 A 또는 B에 따라 제1항 내지 제10항중 어느 한 항의 화합물 또는 이의 약제학적으로 허용되는 염을 제조하는 방법.
    참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910016528A 1990-09-20 1991-09-20 1-페닐-3-아릴-2-프로핀-1-온화합물, 이를 함유하는 약제학적 조성물 및 이의 제조방법 KR100198045B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US58541190A 1990-09-20 1990-09-20
US7/585,411 1990-09-20
US07/585,411 1990-09-20
US59550690A 1990-10-11 1990-10-11
US7/595,506 1990-10-11
US07/595506 1990-10-11

Publications (2)

Publication Number Publication Date
KR920006317A true KR920006317A (ko) 1992-04-27
KR100198045B1 KR100198045B1 (ko) 1999-06-15

Family

ID=27079378

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910016528A KR100198045B1 (ko) 1990-09-20 1991-09-20 1-페닐-3-아릴-2-프로핀-1-온화합물, 이를 함유하는 약제학적 조성물 및 이의 제조방법

Country Status (16)

Country Link
EP (1) EP0476645B1 (ko)
JP (1) JP3314877B2 (ko)
KR (1) KR100198045B1 (ko)
CN (1) CN1060092A (ko)
AT (1) ATE127455T1 (ko)
AU (1) AU640523B2 (ko)
CA (1) CA2051504C (ko)
DE (1) DE69112747T2 (ko)
ES (1) ES2079539T4 (ko)
FI (1) FI914410A (ko)
HU (1) HUT59100A (ko)
IE (1) IE913299A1 (ko)
IL (1) IL99512A0 (ko)
NO (1) NO913685L (ko)
NZ (1) NZ239863A (ko)
PT (1) PT99010A (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713635B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés propynyl bi-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
CN103239713A (zh) * 2013-05-28 2013-08-14 东南大学 一种糖尿病肾病微炎症小鼠模型的建立方法
CN105693617B (zh) * 2014-11-24 2018-06-08 中国科学院大连化学物理研究所 一种tmsn3参与的还原环化反应制备4-咪唑甲醛衍生物的方法
KR102316790B1 (ko) 2020-12-11 2021-10-22 바이오플라스틱스 이노베이션스 리미티드 바이오매스로부터 유도된 반응속도조절제 및 분자량증가제를 첨가하여 제조된 생분해성 폴리에스터수지 및 그 제조방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051494C (en) * 1990-09-20 2006-03-14 Robert J. Dinerstein 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors

Also Published As

Publication number Publication date
PT99010A (pt) 1992-08-31
AU8452791A (en) 1992-03-26
IL99512A0 (en) 1992-08-18
DE69112747T2 (de) 1996-02-01
NO913685L (no) 1992-03-23
IE913299A1 (en) 1992-04-22
KR100198045B1 (ko) 1999-06-15
ES2079539T4 (es) 1997-01-16
AU640523B2 (en) 1993-08-26
NO913685D0 (no) 1991-09-19
NZ239863A (en) 1993-10-26
HU913009D0 (en) 1992-01-28
FI914410A (fi) 1992-03-21
JPH0710751A (ja) 1995-01-13
CN1060092A (zh) 1992-04-08
EP0476645B1 (en) 1995-09-06
DE69112747D1 (de) 1995-10-12
HUT59100A (en) 1992-04-28
CA2051504A1 (en) 1992-03-21
JP3314877B2 (ja) 2002-08-19
CA2051504C (en) 2003-04-15
FI914410A0 (fi) 1991-09-19
ATE127455T1 (de) 1995-09-15
ES2079539T3 (es) 1996-01-16
EP0476645A1 (en) 1992-03-25

Similar Documents

Publication Publication Date Title
KR920006316A (ko) 칼슘 흡수 억제제
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
RU95108332A (ru) Производные индола и их таутомерные формы, смеси их изомеров и фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозин-киназы активностью и способ торможения зависящего от протеин-тирозин-киназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека
FI882081A (fi) 2-substituerade e-fusionerade (1,2,4) triazolo(1,5-c) pyrimidiner, farmaceutiska kompositioner och deras anvaendning.
DE68914292T2 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
DK452682A (da) Hidtil ukendte imidazolderivater, fremgangsmaade til deres fremstilling og farmaceutiske praeparater indeholdende dem
KR900015721A (ko) 신규 방법 및 화합물들
ATE89547T1 (de) Dopamin-vorlaeufer.
ES444870A1 (es) Procedimiento para preparar derivados de oxadiazolinona.
RU94036760A (ru) Производные триазина, его получение и использование
KR920006317A (ko) 칼슘 흡수 억제제
KR920006277A (ko) 칼슘 흡수 억제제
FR2655043B1 (fr) Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US4008326A (en) Substituted ureas and thioureas and pharmaceutical compositions thereof
RU2208611C2 (ru) Сульфонамидозамещенные хроманы и фармацевтическая композиция
DK216186D0 (da) Hexensyrer
NO166321C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridinforbindelser.
ES8702399A1 (es) Un procedimiento para preparar derivdos de 1,5-benzoxatiepina
UA41903C2 (uk) Спосіб одержання заміщених похідних імідазолу або їх фармацевтично прийнятних солей
ATE34739T1 (de) Neue 2-pyridin-thiol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DK601783D0 (da) Resorcinderivater
FR2655044B1 (fr) Derives d'(hetero) arylmethyloxy-4 phenyl tetrazole et oxadiazole, leur procede de preparation et leur application en therapeutique.
KR910006290A (ko) 피리미도인돌 유도체 및 이의 제조방법
ES8500925A1 (es) "procedimiento para la preparacion de n-(2-(((5-(dimetilamino)-metil-2-furanil) metil) tio) etil) -n'- metil-2-nitro 1,1-etenodiamina"
MY104048A (en) New allylaminoethylazoles.

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050224

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee